Curis, Inc. (NASDAQ:CRIS)

CAPS Rating: 4 out of 5

A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.

Recs

1
Player Avatar waderjw (65.48) Submitted: 7/14/2011 10:54:21 AM : Outperform Start Price: $3.90 CRIS Score: -112.85

They're having good trial runs on their cancer drugs.

Featured Broker Partners


Advertisement